Abstract
This article reviews the literature that examines whether exposure to psychostimulants or antidepressants precipitates or exacerbates manic symptoms, or decreases the age at onset of mania in pediatric populations. A PubMed search using relevant key words identified studies targeting five distinct clinical groups: (i) youth without a diagnosis of bipolar disorder (BD) at the time of exposure to psychostimulants; (ii) youth with a diagnosis of BD at the time of exposure to psychostimulants; (iii) youth without a diagnosis of BD at the time of exposure to antidepressants; (iv) youth with a diagnosis of BD at the time of exposure to antidepressants; and (v) youth who develop BD after exposure to these medications.
In patients with attention-deficit hyperactivity disorder (ADHD), the risk for mania was found to be relatively low with the use of psychostimulants. For patients with BD and ADHD, effective mood stabilization is important prior to adding a stimulant. For children with depression and/or anxiety, the risk of antidepressant-induced mania (AIM) was generally low (<2%), but the risk of general ‘activation’ secondary to a selective serotonin reuptake inhibitor (SSRI) may be greater (2–10%). However, rates of AIM in specialty clinics appear to be much higher. SSRIs may be particularly problematic in specific populations, such as those with some symptoms of mania or a family history of BD, but the precise risk is unknown. There is no clear evidence that stimulants or SSRIs accelerate the natural course of BD development in overall samples, but in individual cases prescribers should proceed cautiously when using these agents in youth already at risk for developing BD, such as those with ADHD and mood dysregulation, a history of prior AIM, a history of psychosis, or a family history of BD.
Similar content being viewed by others
References
Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003 Jan; 157(1): 17–25
Greenhill L, Beyer DH, Finkleson J, et al. Guidelines and algorithms for the use of methylphenidate in children with attention-deficit/hyperactivity disorder. J Atten Disord 2002; 6Suppl. 1: S89–100
Pliszka S, Dodson WW, Spencer TJ. Current treatments of attention-deficit/hyperactivity disorder. CNS Spectr 2000 May; 5 (5 Suppl. 3): S1–7
Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(7): 894–921
Hughes C, Emslie G, Crismon M, et al. Texas children’s medication algorithm project: update from Texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(6): 667–86
Boylan K, Romero S, Birmaher B. Psychopharmacologic treatment of pediatric major depressive disorder. Psychopharmacology 2007; 191(1): 27–38
American Psychiatric Association. Diagnostic criteria from DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000
Carlson GA, Kelly KL. Manic symptoms in psychiatrically hospitalized children: what do they mean? J Affect Disord 1998 Nov; 51(2): 123–35
Carlson GA, Loney J, Salisbury H, et al. Stimulant treatment in young boys with symptoms suggesting childhood mania: a report from a longitudinal study. J Child Adolesc Psychopharmacol 2000 Fall; 10(3): 175–84
Galanter CA, Carlson GA, Jensen PS, et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. J Child Adolesc Psychopharmacol 2003 Summer; 13(2): 123–36
Arnold L, Abikoff H, Cantwell D, et al. NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. J Atten Disord 1997; 2(3): 141–58
Achenbach T. Child behavior checklist/4–18. Burlington (VT): University of Vermont, Department of Psychiatry, 1991
Shaffer D, Fisher P, Dulcan M, et al. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA study. J Am Acad Child Adolesc Psychiatry 1996; 35(7): 865–77
Tillman R, Geller B. Controlled study of switching from attention-deficit/hyperactivity disorder to a prepubertal and early adolescent bipolar I disorder phenotype during 6-year prospective follow-up: rate, risk, and predictors. Dev Psychopathol 2006 Fall; 18(4): 1037–53
Shaffer D, Gould MS, Brasic J, et al. A children’s global assessment scale (CGAS). Arch Gen Psychiatry 1983 Nov; 40(11): 1228–31
Scheffer R, Kowatch R, Carmody T, et al. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005; 162(1): 58–64
Guy W, Bonato R. CGI: Clinical global impressions. ECDEU assessment manual for psychopharmacology. Chevy Chase (MD): National Institute of Mental Health, 1976: 217–22
Young R, Biggs J, Ziegler V, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133(5): 429–35
Findling RL, Short EJ, McNamara NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(11): 1445–53
Poznanski E, Mokros H, Services WP. Children’s Depression Rating Scale. Rev. (CDRS-R). Los Angeles (CA): Western Psychological Services, 1996
Chang K, Nayar D, Howe M, et al. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol 2009; 19(5): 547–51
DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD rating scale-IV: checklists, norms, and clinical interpretation. New York: Guilford, 1998
Zeni CP, Tramontina S, Ketzer CR, et al. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J Child Adolesc Psychopharmacol 2009 Oct; 19(5): 553–61
Faedda G. Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review. J Affect Disord 2004; 82(1): 149–58
Findling RL, Lingler J, Rowles BM, et al. A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. J Child Adolesc Psychopharmacol 2008; 18(6): 615–21
Baumer F, Howe M, Gallelli K, et al. A pilot study of antidepressant-induced mania in pediatric bipolar disorder: characteristics, risk factors, and the serotonin transporter gene. Biol Psychiatry 2006; 60(9): 1005–12
Biederman J, Mick E, Spencer TJ, et al. Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. J Child Adolesc Psychopharmacol 2000 Fall; 10(3): 185–92
DelBello M, Soutullo C, Hendricks W, et al. Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disord 2001; 3(2): 53–7
Geller B, Williams M, Zimerman B, et al. Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS). St Louis (MO): Washington University, 1996
Martin A, Young C, Leckman JF, et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004 Aug; 158(8): 773–80
Chang K, Saxena K, Howe M, et al. Psychotropic medication exposure and age at onset of bipolar disorder in offspring of parents with bipolar disorder. J Child Adolesc Psychopharmacol 2010; 20(1): 25–32
Koehler-Troy C, Strober M, Malenbaum R. Methylphenidate-induced mania in a prepubertal child. J Clin Psychiatry 1986 Nov; 47(11): 566–7
Schmidt K, Delaney MA, Jensen M, et al. Methylphenidate challenge in a manic boy. Biol Psychiatry 1986 Sep; 21(11): 1107–9
Tversky A, Kahneman D. Availability: a heuristic for judging frequency and probability. Cogn Psychol 1973; 5: 207–32
Bornstein BH, Emler AC. Rationality in medical decision making: a review of the literature on doctors’ decision-making biases. J Eval Clin Pract 2001 May; 7(2): 97–107
Geller B, Tillman R, Craney JL, et al. Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. Arch Gen Psychiatry 2004 May; 61(5): 459–67
Singh MK, DelBello MP, Kowatch RA, et al. Co-occurrence of bipolar and attention-deficit hyperactivity disorders in children. Bipolar Disord 2006 Dec; 8(6): 710–20
Thorndike RL. Personnel selection: test and measurement techniques. New York: John Wiley, 1949
Pearson K. Mathematical contributions to the theory of evolution. XI: On the influence of natural selection on the variability and correlation of organs. Philosophical transactions of the Royal Society of London Series A, containing papers of a mathematical or physical character. 1903; 200: 1–66
Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005 Mar; 44(3): 213–35
Soutullo CA, DelBello MP, Ochsner JE, et al. Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. J Affect Disord 2002 Aug; 70(3): 323–7
Joseph MF, Youngstrom EA, Soares JC. Antidepressant-coincident mania in children and adolescents treated with selective serotonin reuptake inhibitors. Future Neurol 2009; 4(1): 87–102
Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994 Apr; 164(4): 549–50
Altshuler L, Post R, Leverich G, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152(8): 1130–8
McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder [published erratum appears in J Am Acad Child Adolesc Psychiatry 2007; 46 (6): 786]. Work Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 2007; 46(1): 107–25
Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 2003 Dec; 5(6): 407–20
Hammad T. Results of the analysis of suicidality in pediatric trials of newer antidepressants. Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee September 13–14, 2004: Division of Neuropharmacological Drug Products Center for Drug Evaluation and Research [slide 96; online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4065S1_08_FDA-Hammad.ppt [Accessed 2011 May 26]
Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 2005; 46(7): 735–54
Carlson GA, Mick E. Drug-induced disinhibition in psychiatrically hospitalized children. J Child Adolesc Psychopharmacol 2003 Summer; 13(2): 153–63
Emslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45(12): 1440–55
Emslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry 2006 Dec; 45(12): 1440–55
Wilens TE, Biederman J, Kwon A, et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 2003 Summer; 13(2): 143–52
Go FS, Malley EE, Birmaher B, et al. Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 1998; 8(1): 73–80
Masi G. Obsessive-compulsive bipolar comorbidity: focus on children and adolescents. J Affect Disord 2004; 78(3): 175–83
Brent DA. The rewards of reducing risk. Arch Pediatr Adolesc Med 2004 Aug; 158(8): 824–5
Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997 Nov; 54(11): 1031–7
Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002 Oct; 41(10): 1205–15
Geller B, Cooper TB, Zimerman B, et al. Lithium for prepubertal depressed children with family history predictors of future bipolarity: a double-blind, placebo-controlled study. J Affect Disord 1998 Nov; 51(2): 165–75
DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009 Aug; 11(5): 483–93
Chang K, Dienes K, Blasey C, et al. Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. J Clin Psychiatry 2003; 64(8): 936–42
DelBello M, Adler C, Whitsel R, et al. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 2007; 68(5): 781–8
Goldstein BI, Levitt AJ. Prevalence and correlates of bipolar I disorder among adults with primary youth-onset anxiety disorders. J Affect Disord 2007; 103(1–3): 187–95
Henin A, Biederman J, Mick E, et al. Childhood antecedent disorders to bipolar disorder in adults: a controlled study. J Affect Disord 2007; 99(1–3): 51–7
Johnson JG, Cohen P, Brook JS. Associations between bipolar disorder and other psychiatric disorders during adolescence and early adulthood: a community-based longitudinal investigation. Am J Psychiatry 2000; 157(10): 1679–81
Daray FM, Thommi SB, Ghaemi SN. The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. Bipolar Disord 2010; 12(7): 702–6
Biederman J, Mick E, Faraone SV, et al. Pediatric mania: a developmental subtype of bipolar disorder? Biol Psychiatry 2000 Sep 15; 48(6): 458–66
Geller B, Fox L, Clark K. Rate and predictors of prepubertal bipolarity during follow-up of 6-to 12-year-old depressed children. J Am Acad Child Adolesc Psychiatry 1994; 33(4): 461–8
Henry C, Sorbara F, Lacoste J, et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001; 62(4): 249–55
Truman C, Goldberg J, Nassir Ghaemi S, et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEPBD). J Clin Psychiatry 2007; 68(10): 1472–9
Wehr T, Goodwin F. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979; 36(5): 555–9
Goldberg J, Nassir Ghaemi S. Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression. Bipolar Disord 2005; 7: 3–12
Sachs G, Printz D, Kahn D, et al. The expert consensus guideline series: medication treatment of bipolar disorder. Postgrad Med 2000; 1: 1–104
Salvadore G, Quiroz JA, Machado-Vieira R, et al. The neurobiology of the switch process in bipolar disorder. J Clin Psychiatry 2010; 71(11): 1488–501
Faedda G, Baldessarini R, Glovinsky I, et al. Pediatric bipolar disorder: phenomenology and course of illness. Bipolar Disord 2004; 6(4): 305–13
Fitzmaurice G. Regression to the mean. Nutrition 2000 Jan; 16(1): 80–1
Geller B, Craney JL, Bolhofner K, et al. Two-year prospective follow-up of children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry 2002 Jun; 159(6): 927–33
Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45(3): 298–304
Patel N, DelBello M, Cecil K, et al. Lithium treatment effects on myoinositol in adolescents with bipolar depression. Biol Psychiatry 2006; 60(9): 998–1004
Reichart C. Earlier onset of bipolar disorder in children by antidepressants or stimulants? An hypothesis. J Affect Disord 2004; 78(1): 81–4
Chang K, Steiner H, Ketter T. Psychiatric phenomenology of child and adolescent bipolar offspring. J Am Acad Child Adolesc Psychiatry 2000; 39(4): 453–60
Akiskal H. Developmental pathways to bipolarity: are juvenile-onset depressions pre-bipolar? J Am Acad Child Adolesc Psychiatry 1995; 34(6): 754–63
Geller B, Zimerman B, Williams M, et al. Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am J Psychiatry 2001; 158(1): 125–7
DelBello MP, Carlson GA, Tohen M, et al. Rates and predictors of developing a manic or hypomanic episode 1 to 2 years following a first hospitalization for major depression with psychotic features. J Child Adolesc Psychopharmacol 2003 Summer; 13(2): 173–85
Cicero D, El-Mallakh R, Holman J, et al. Antidepressant exposure in bipolar children. Psychiatry 2003; 66(4): 317–22
Pagano M, Demeter C, Faber J, et al. Initiation of stimulant and antide-pressant medication and clinical presentation in juvenile bipolar I disorder. Bipolar Disord 2008; 10(2): 334–41
Post R, Rubinow D, Ballenger J. Conditioning and sensitisation in the longitudinal course of affective illness. Br J Psychiatry 1986; 149(2): 191–201
Chang K, Howe M, Gallelli K, et al. Prevention of pediatric bipolar disorder. Ann N Y Acad Sci 2006; 1094(1): 235–47
Chang K, Steiner H, Ketter T. Studies of offspring of parents with bipolar disorder. Am J Med Genet C Semin Med Genet 2003 Nov 15; 123C(1): 26–35
Carlson GA. The bottom line. J Child Adolesc Psychopharmacol 2003 Summer; 13(2): 115–8
Hellander M. Medication-induced mania: ethical issues and the need for more research. J Child Adolesc Psychopharmacol 2003 Summer; 13(2): 199
Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108(5): e83
Cheung A, Dewa C, Levitt A. Clinical review of mania, hostility and suicide-related events in children and adolescents treated with antidepressants. Paediatr Child Health 2005; 10(8): 457–63
Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol 2006 Feb–Apr; 16(1–2): 159–69
Strober M, Carlson G. Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three-to four-year prospective follow-up investigation. Arch Gen Psychiatry 1982; 39(5): 549–55
Rao U, Ryan N, Birmaher B, et al. Unipolar depression in adolescents: clinical outcome in adulthood. J Am Acad Child Adolesc Psychiatry 1995; 34(5): 566–78
Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996; 35(6): 705–15
Chang KD. Challenges in the diagnosis and treatment of pediatric bipolar depression. Dialogues Clin Neurosci 2009; 11(1): 73–80
Miklowitz DJ, Axelson DA, Birmaher B, et al. Family-Focused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial. Arch Gen Psychiatry 2008 Sep 1; 65(9): 1053–61
March JS. Multidimensional anxiety scale for children. North Tonawanda (NY): Multi-Health Systems, 1998
Shaffer D, Scott M, Wilcox H, et al. The Columbia Suicide Screen: validity and reliability of a screen for youth suicide and depression. J Am Acad Child Adolesc Psychiatry 2004; 43(1): 71–9
Narayan V, Haddad PM. Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria. J Psychopharmacol 2011 Mar; 25(3): 306–13
Acknowledgments and Disclosures
The preparation of this article was not supported by any funding. Dr Chang has received funding and/or honoraria from the following organizations over the past 5 years: GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Bristol-Myers Squibb, Otsuka, Abbott, and Merck. Dr Goldsmith and Dr Singh have no conflicts of interest to report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goldsmith, M., Singh, M. & Chang, K. Antidepressants and Psychostimulants in Pediatric Populations. Pediatr-Drugs 13, 225–243 (2011). https://doi.org/10.2165/11591660-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11591660-000000000-00000